NASDAQ:ALDX - Aldeyra Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.00
  • Forecasted Upside: 240.31 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.64
▲ +0.05 (0.66%)
1 month | 3 months | 12 months
Get New Aldeyra Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALDX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$26.00
▲ +240.31% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Aldeyra Therapeutics in the last 3 months. The average price target is $26.00, with a high forecast of $32.00 and a low forecast of $15.00. The average price target represents a 240.31% upside from the last price of $7.64.
Buy
The current consensus among 6 investment analysts is to buy stock in Aldeyra Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/16/2020BTIG ResearchInitiated CoverageBuy$29.00High
i
9/22/2020Alliance Global PartnersInitiated CoverageBuy$32.00Medium
i
8/11/2020CitigroupLower Price TargetBuy$24.00 ➝ $22.00High
i
8/7/2020OppenheimerReiterated RatingBuy$15.00High
i
Rating by Justin Kim at Oppenheimer Holdings Inc.
7/7/2020OppenheimerInitiated CoverageBuy$15.00Low
i
Rating by Justin Kim at Oppenheimer Holdings Inc.
6/4/2020OppenheimerInitiated CoverageBuy$15.00Low
i
Rating by Justin Kim at Oppenheimer Holdings Inc.
5/26/2020Janney Montgomery ScottReiterated RatingBuy ➝ Market Perform$28.00Low
i
5/26/2020LaidlawReiterated RatingBuy$30.00Low
i
5/20/2020OppenheimerInitiated CoverageBuy$12.00High
i
Rating by Justin Kim at Oppenheimer Holdings Inc.
5/11/2020OppenheimerInitiated CoverageOutperform$12.00High
i
10/17/2019Cantor FitzgeraldReiterated RatingOverweight$33.00High
i
Rating by L. Chen at Cantor Fitzgerald
6/25/2019Cantor FitzgeraldSet Price TargetBuy$33.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
5/10/2019Canaccord GenuityReiterated RatingBuy$35.00 ➝ $20.00High
i
3/26/2019CitigroupBoost Price TargetBuy ➝ Positive$32.00 ➝ $38.00Medium
i
3/26/2019Cantor FitzgeraldReiterated RatingBuy$30.00 ➝ $35.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
3/8/2019Cantor FitzgeraldSet Price TargetBuy$30.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/28/2019Cantor FitzgeraldSet Price TargetBuy$30.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
1/29/2019Cantor FitzgeraldSet Price TargetBuy$30.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
12/4/2018CitigroupInitiated CoverageBuy ➝ Buy$23.00High
i
11/14/2018Cantor FitzgeraldReiterated RatingBuy$30.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
10/4/2018Cantor FitzgeraldSet Price TargetBuy$30.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
9/27/2018Janney Montgomery ScottBoost Price TargetBuy ➝ Positive$28.00High
i
Rating by Esther Hong at Janney Montgomery Scott
9/26/2018Canaccord GenuityBoost Price TargetBuy ➝ Positive$27.00 ➝ $35.00High
i
9/26/2018Stifel NicolausBoost Price TargetBuy ➝ In-Line$16.00 ➝ $36.00High
i
9/26/2018Cantor FitzgeraldSet Price TargetPositive ➝ Overweight$23.00 ➝ $30.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
9/13/2018Janney Montgomery ScottInitiated CoverageBuy ➝ BuyHigh
i
9/5/2018Cantor FitzgeraldSet Price TargetBuy$23.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
8/27/2018Cantor FitzgeraldSet Price TargetBuy$23.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
8/10/2018Canaccord GenuityReiterated RatingBuy$27.00Low
i
8/9/2018Cantor FitzgeraldSet Price TargetBuy$23.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
6/26/2018Cantor FitzgeraldReiterated RatingBuy$23.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
5/15/2018Cantor FitzgeraldSet Price TargetBuy$23.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
4/9/2018CowenReiterated RatingHoldLow
i
3/29/2018Cantor FitzgeraldSet Price TargetBuy$23.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
3/13/2018Canaccord GenuityReiterated RatingBuy$27.00Low
i
3/1/2018Seaport Global SecuritiesReiterated RatingBuyLow
i
Rating by V. Bernardino at Seaport Global Securities
1/26/2018Seaport Global SecuritiesInitiated CoverageBuy$13.00Medium
i
Rating by C. Davis at Seaport Global Securities
10/24/2017Cantor FitzgeraldInitiated CoverageOverweight$22.00N/A
i
Rating by E. Piros at Cantor Fitzgerald
9/14/2017CowenReiterated RatingOutperform$9.00 ➝ $14.00High
i
9/13/2017Canaccord GenuityReiterated RatingBuy ➝ Buy$12.00 ➝ $27.00Medium
i
Rating by John Newman at Canaccord Genuity
8/9/2017HC WainwrightSet Price TargetBuy$18.00Low
i
Rating by Corey Davis at HC Wainwright
6/15/2017HC WainwrightSet Price TargetBuy$18.00Low
i
Rating by Corey Davis at HC Wainwright
6/14/2017Canaccord GenuitySet Price TargetBuy$12.00Low
i
Rating by John Newman at Canaccord Genuity
5/31/2017Stifel NicolausReiterated RatingBuy$16.00Medium
i
4/1/2017HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Corey Davis at HC Wainwright
3/31/2017Canaccord GenuityReiterated RatingBuy$15.00 ➝ $12.00Low
i
Rating by John Newman at Canaccord Genuity
3/31/2017CowenReiterated RatingBuy$20.00Low
i
12/25/2016Canaccord GenuitySet Price TargetBuy$15.00N/A
i
Rating by John Newman at Canaccord Genuity
11/18/2016HC WainwrightReiterated RatingBuyN/A
i
11/15/2016CowenReiterated RatingBuyN/A
i
9/26/2016HC WainwrightInitiated CoverageBuy$18.00N/A
i
Rating by S. Ramakanth at HC Wainwright
7/1/2016Stifel NicolausInitiated CoverageBuy$16.00N/A
i
5/10/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
3/1/2016CowenReiterated RatingOutperformN/A
i
Rating by Ritu Baral at Cowen Inc
2/29/2016Janney Montgomery ScottReiterated RatingBuyN/A
i
Rating by Roy Buchanan at Janney Montgomery Scott
1/13/2016CowenReiterated RatingOutperform$15.00N/A
i
Rating by Ritu Baral at Cowen Inc
12/17/2015Janney Montgomery ScottReiterated RatingBuy$15.00N/A
i
11/13/2015Canaccord GenuityReiterated RatingBuy$15.00N/A
i
Rating by Corey Davis at Canaccord Genuity
(Data available from 10/24/2015 forward)
Aldeyra Therapeutics logo
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Read More

Today's Range

Now: $7.64
$7.25
$7.71

50 Day Range

MA: $7.01
$5.85
$8.10

52 Week Range

Now: $7.64
$1.48
$8.70

Volume

266,831 shs

Average Volume

635,551 shs

Market Capitalization

$295.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02